Relapsing-Remitting Multiple Sclerosis (RRMS) Clinical Trial
Official title:
Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)
This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily oral doses of IMU-838 (vidofludimus calcium), a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), 30 mg/day and 45 mg/day in the main study, cohort 1 (and 10 mg/day for the patients in the cohort 2 substudy), in patients with RRMS and evidence of active disease. The trial consists of a screening period, a blinded 24-week main treatment period, and an optional initially blinded, then open-label extended treatment period of up to 9.5 years. About 40 centers are planned to participate in Romania, Bulgaria, Ukraine, and Poland; potential additional centers in Hungary and Croatia were not used. The study started with 195 patients in the main group (cohort 1) planned to be randomized 1:1:1 to treatment with 30 mg/day or 45 mg/day IMU-838, or placebo (65 patients each) in the main treatment period. During the extended treatment period, patients were initially re-randomized so that patients previously on placebo were re-randomized 1:1 to treatment with 30 g/day or 45 mg/day IMU-838, all other patients were re-randomized to the same treatment they previously received. With approval of Protocol Version 3.0, a sub-study patient group (cohort 2) has been added with up to 60 patients, randomized to placebo or 10 mg IMU-838 for 24 weeks after which the option is available to continue into the extended treatment period and the recommended dose of 30 mg/day. However, based on discussion between investigator and patient 45 mg/day IMU-838/day may also be used.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05177523 -
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
|
||
| Withdrawn |
NCT05172466 -
Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab
|
N/A | |
| Recruiting |
NCT05304520 -
A Study for Tysabri Participant Preference
|
||
| Completed |
NCT04115488 -
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
|
Phase 3 | |
| Recruiting |
NCT05811416 -
A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
|
||
| Completed |
NCT02587065 -
Plegridy Satisfaction Study in Participants
|
Phase 4 | |
| Not yet recruiting |
NCT02568111 -
Brimonidine Tartrate for the Treatment of Injection Related Erythema
|
Phase 4 | |
| Terminated |
NCT01633112 -
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
|
Phase 3 | |
| Completed |
NCT01738347 -
Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).
|
Phase 1 | |
| Terminated |
NCT02881567 -
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
|
Phase 3 | |
| Not yet recruiting |
NCT05245344 -
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study
|